Discovery and antiproliferative evaluation of new quinoxalines as potential DNA intercalators and topoisomerase II inhibitors.
Antineoplastic Agents
/ chemical synthesis
Apoptosis
/ drug effects
Caco-2 Cells
Cell Cycle
/ drug effects
Cell Line, Tumor
Cell Proliferation
/ drug effects
DNA Topoisomerases, Type II
/ metabolism
DNA, Neoplasm
/ chemistry
Dose-Response Relationship, Drug
Drug Discovery
Drug Screening Assays, Antitumor
Hep G2 Cells
Humans
Molecular Docking Simulation
Molecular Structure
Quinoxalines
/ chemical synthesis
Structure-Activity Relationship
Topoisomerase II Inhibitors
/ chemical synthesis
DNA intercalator
anticancer
apoptosis
molecular docking
quinoxalines
topoisomerase II
Journal
Archiv der Pharmazie
ISSN: 1521-4184
Titre abrégé: Arch Pharm (Weinheim)
Pays: Germany
ID NLM: 0330167
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
18
04
2019
revised:
25
07
2019
accepted:
26
07
2019
pubmed:
30
8
2019
medline:
9
4
2020
entrez:
30
8
2019
Statut:
ppublish
Résumé
In continuation of our previous work on the design and synthesis of topoisomerase II (Topo II) inhibitors and DNA intercalators, a new series of quinoxaline derivatives were designed and synthesized. The synthesized compounds were evaluated for their cytotoxic activities against a panel of three cancer cell lines (Hep G-2, Hep-2, and Caco-2). Compounds 18b, 19b, 23, 25b, and 26 showed strong potencies against all tested cell lines with IC
Identifiants
pubmed: 31463953
doi: 10.1002/ardp.201900123
doi:
Substances chimiques
Antineoplastic Agents
0
DNA, Neoplasm
0
Quinoxalines
0
Topoisomerase II Inhibitors
0
DNA Topoisomerases, Type II
EC 5.99.1.3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1900123Informations de copyright
© 2019 Deutsche Pharmazeutische Gesellschaft.